A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.

被引：0
|
作者：
Ishikawa, Mitsuya
Kitagawa, Ryo
Shibata, Taro
Tokunaga, Hideki
Iwata, Takashi
Nishio, Shin
Takada, Toshio
Mori, Masahiko
Horie, Koji
Kudaka, Wataru
Kagabu, Masahiro
Tanikawa, Michihiro
Kobayashi, Hiroaki
Yaegashi, Nobuo
机构：
[1] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan
[2] Moriya Daiichi Gen Hosp, Dept Gynecol & Obstet, Ibaraki, Japan
[3] Natl Canc Ctr, Operat Off, Japan Clin Oncol Grp Data Ctr, Tokyo, Japan
[4] Tohoku Univ Hosp, Dept Gynecol, Sendai, Miyagi, Japan
[5] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan
[6] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan
[7] Kitasato Univ, Dept Obstet & Gynecol, Sch Med, Sagamihara, Kanagawa, Japan
[8] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, Nagoya, Aichi, Japan
[9] Saitama Canc Ctr, Dept Gynecol, Saitama, Japan
[10] Univ Ryukyus, Grad Sch Med Sci, Dept Obstet & Gynecol, Nishihara, Okinawa, Japan
[11] Iwate Med Univ, Dept Obstet & Gynecol, Sch Med, Morioka, Iwate, Japan
[12] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[13] Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima, Japan
[14] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6027
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis
    Ishikawa, Mitsuya
    Shibata, Taro
    Iwata, Takashi
    Nishio, Shin
    Takada, Toshio
    Suzuki, Shiro
    Horie, Koji
    Kudaka, Wataru
    Kagabu, Masahiro
    Tanikawa, Michihiro
    Kitagawa, Ryo
    Takekuma, Munetaka
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    GYNECOLOGIC ONCOLOGY, 2021, 162 (02) : 292 - 298
  • [2] Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311)
    Ishikawa, Mitsuya
    Shibata, Taro
    Kataoka, Tomoko
    Takekuma, Munetaka
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    Satoh, Toyomi
    Gynecol Canc Study Grp
    Japan Clin Oncol Grp
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 692 - 700
  • [3] A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311)
    Ishikawa, Mitsuya
    Nakamura, Kenichi
    Shibata, Taro
    Tanaka, Kiyo
    Kitagawa, Ryo
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (12) : 1096 - 1100
  • [4] A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).
    Kitagawa, Ryo
    Ishikawa, Mitsuya
    Shibata, Taro
    Miyamoto, Kenichi
    Kobayashi, Hiroaki
    Onda, Takashi
    Takekuma, Munetaka
    Takahashi, Fumiaki
    Yokota, Harushige
    Tanikawa, Michihiro
    Mizuno, Mika
    Oishi, Tetsuro
    Aoki, Yoichi
    Nishio, Shin
    Iwata, Takashi
    Yaegashi, Nobuo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] DOSE-DENSE, WEEKLY PACLITAXEL AND CARBOPLATIN WITH OR WITHOUT BEVACIZUMAB, IN METASTATIC OR RECURRENT CERVICAL CARCINOMA (FINAL ANALYSIS OF JCOG1311)
    Ishikawa, Mitsuya
    Shibata, Taro
    Kataoka, Tomoko
    Takekuma, Munetaka
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    Sato, Toyomi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A38 - A38
  • [6] PHASE II TRIAL OF PACLITAXEL, CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT OR PERSISTENT CERVICAL CANCER
    Suzuki, K.
    Nagao, S.
    Kaneda, M.
    Sibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Sudo, T.
    Yamaguchi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 411 - 411
  • [7] Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer
    Suzuki, Kazuhiro
    Nagao, Shoji
    Shibutani, Takashi
    Yamamoto, Kasumi
    Jimi, Tomoatsu
    Yano, Hiroko
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Yamaguchi, Satoshi
    GYNECOLOGIC ONCOLOGY, 2019, 154 (03) : 554 - 557
  • [8] Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
    Shawky, Hanan
    Tawfik, Hesham
    Hewidy, Medhat
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2014, 26 (03) : 139 - 145
  • [9] A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.
    Aghajanian, Carol
    Filiaci, Virginia L.
    Dizon, Don S.
    Carlson, Jay
    Powell, Matthew A.
    Secord, Angeles Alvarez
    Tewari, Krishnansu Sujata
    Bender, David
    O'Malley, David M.
    Stuckey, Ashley
    Rotmensch, Jacob
    Levine, Douglas A.
    Lankes, Heather A.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)
    Simpkins, Fiona
    Drake, Richard
    Escobar, Pedro F.
    Nutter, Benjamin
    Rasool, Nabila
    Rose, Peter G.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 240 - 245
12345